Drug
Ak104
Ak104: highest development phase Phase 3, developed by Akeso. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK104 NCT04982237 | Phase 3 | Cervical Cancer |
| AK104 NCT05990127 | Phase 3 | Locally Advanced or Metastatic NSCLC |
| AK104 NCT05227651 | Phase 2 | Cervical Cancer |
| AK104 NCT05932212 | Phase 2 | Vulvar Cancer |
| AK104 (before the change) NCT05559554 | Phase 1 | Healthy Male Subjects |
Latest
No recent events.
Follow Ak104 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.